To Demonstrate the Relative Bioavailability of Desipramine Hydrochloride Tablets
NCT00913822 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2017-03-28
Summary
To demonstrate the relative bioavailability of Desipramine Hydrochloride tablets.
Conditions
Interventions
- DRUG
-
Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)
- DRUG
-
Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Jules Kann, M.D. · University of Pittsburgh
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 1987-12-31
- Primary Completion
- 1987-12-31
- Completion
- 1987-12-31
More Related Trials
-
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
NCT03606395 ·Status: COMPLETED ·Phase: PHASE1
-
"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"
NCT06564818 ·Status: RECRUITING ·Phase: PHASE3
-
Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder
NCT01413932 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression
NCT00070694 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111539 ·Status: TERMINATED ·Phase: PHASE3
-
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401 ·Status: RECRUITING ·Phase: PHASE3
-
To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01123707 ·Status: TERMINATED ·Phase: PHASE3
-
Treatment Response of Geriatric Depression
NCT00754936 ·Status: COMPLETED ·Phase: NA
-
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06911112 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Test Different Doses of BI 1569912 in People With Depression
NCT06558344 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
NCT07276997 ·Status: RECRUITING ·Phase: PHASE2
-
Relative Bioavailability and Food Effect Study for GSK163090 in Healthy Male and Female Volunteers
NCT00536679 ·Status: COMPLETED ·Phase: PHASE1
-
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021 ·Status: RECRUITING ·Phase: PHASE3
-
Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)
NCT01111552 ·Status: TERMINATED ·Phase: PHASE3
-
Mechanisms of Antidepressant Non-Response in Late-Life Depression
NCT01931202 ·Status: COMPLETED ·Phase: NA
-
The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD
NCT00163059 ·Status: COMPLETED ·Phase: PHASE2
-
Identifying Factors That Predict Antidepressant Treatment Response
NCT00360399 ·Status: COMPLETED ·Phase: NA
-
Depression, Epinephrine, and Platelet Function
NCT00166114 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment Choices for Improving Adherence and Outcome
NCT00194948 ·Status: COMPLETED ·Phase: NA
-
Safety and Pharmacodynamic Study of ABT-436 in Major Depressive Disorder
NCT01380704 ·Status: COMPLETED ·Phase: PHASE1
-
the Safety, Tolerability, and Pharmacokinetics Study of HEC113995
NCT04623814 ·Status: COMPLETED ·Phase: PHASE1
-
A Fifty-two-week Study to Evaluate the Safety of Saredutant in Adult and Elderly Patients With Depression
NCT00250653 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacogenetic Testing in an Outpatient Population of Patients With Depression
NCT02497027 ·Status: COMPLETED ·Phase: NA
-
Desipramine in Infantile Neuroaxonal Dystrophy (INAD).
NCT03726996 ·Status: TERMINATED ·Phase: PHASE4
-
Comparative Responses to 15 Different Antidepressants in Major Depressive Disorder
NCT05952713 ·Status: COMPLETED